Clinicobiochemical Profile and Outcome of Children with Small Molecule Neurometabolic Disorders: A Tertiary Care Hospital Experience from India
- 1 March 2024
- journal article
- research article
- Published by Georg Thieme Verlag KG in Journal of Pediatric Neurology
- Vol. 22 (04) , 287-295
Abstract
Inborn Errors of Metabolism (IEM), though heterogenous, are not uncommon. Neurologic manifestations predominate. Without universal newborn screening, early diagnosis and treatment may lessen neuromorbidity. Hence, this study was done to understand small molecule neurometabolic disorders' presentation, diagnostic clues, and outcome. Small molecule neurometabolic disorder was diagnosed in 45 children (postneonatal onset) over 14 years (2008–2022) in a tertiary care hospital. Clinical and laboratory data were retrospectively analyzed. There were 26 boys and 19 girls. The median age at diagnosis was 19 months (interquartile range [IQR]: 8–38 months). The median diagnostic delay was 12 months in chronic encephalopathy (IQR: 1–24 months) and 1 month (IQR: 0.2–5.5 months) in the acute encephalopathy group (p ≤ 0.01). The presentation mode was chronic encephalopathy/myopathy in 29 (64.4%) and acute encephalopathy in 11 (24.4%). Diagnostic clues included unexplained developmental delay (n = 27, 60%), tone abnormalities (n = 26, 57.7%), movement disorder and ataxia (n = 16, 35.5%), acute encephalopathy (n = 11, 24.4%), neuroregression (n = 10, 22.2%), macrocephaly (n = 10, 22.2%), and alopecia (n = 4, 8.9%). Diagnostic/suggestive blood-spot tandem mass spectrometry (TMS) was seen in 34/38 (89.5%) children. Neuroimaging helped clinch the diagnosis in 17 (47%) children. Diagnostic categories were organic acidemias (n = 25, 55.6%), urea cycle disorders (n = 11, 24.4%), aminoacidopathies (n = 5, 11.1%), and fatty acid oxidation disorders (n = 4, 8.9%). The neurodevelopmental outcome was normal in 13 (28.8%), mild delay in 12 (26.6%), severe delay in 11 (24.4%), 3 deaths (6.6%), and 6 (13.3%) children being lost to follow-up. Overall, the outcome was favorable in 55% of cases. Unexplained developmental delay with tone abnormalities with or without movement disorders is a joint presentation of late-onset neurometabolic diseases. Neuroimaging studies and laboratory tests like blood-spot TMS help identify many small molecule disorders.Keywords
This publication has 25 references indexed in Scilit:
- An international classification of inherited metabolic disorders (ICIMD)Journal of Inherited Metabolic Disease, 2020
- Testing Modalities for Inborn Errors of Metabolism — What a Clinician Needs to Know?Indian Pediatrics, 2019
- Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement DisordersJAMA Neurology, 2018
- Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: Experience of the Pilot Study in Andhra Pradesh, IndiaIndian Journal of Pediatrics, 2011
- Diagnosis of Major Organic Acidurias in Children: Two Years Experience at a Tertiary Care CentreIndian Journal of Clinical Biochemistry, 2011
- Screening for inborn errors of metabolism using automated electrospray tandem mass spectrometry: Study in high-risk Indian populationClinical Biochemistry, 2010
- Profile of inborn errors of metabolism in a tertiary care centre PICUIndian Journal of Pediatrics, 2010
- Yield of additional metabolic studies in neurodevelopmental disordersAnnals of Neurology, 2008
- Impact of inborn errors of metabolism on admission and mortality in a pediatric intensive care unitEuropean Journal of Pediatrics, 2006
- Inborn errors of metabolism (IEM) — an Indian perspectiveIndian Journal of Pediatrics, 2005